3 results
Approved WMOCompleted
To determine the efficacy of the combinations of retifanlimab + INCAGN02385 (TG2) and retifanlimab + INCAGN02385 + INCAGN02390 (TG3) compared with retifanlimab alone (TG1) in the overall study population.
Approved WMORecruiting
Primary Objective: To demonstrate the clinical efficacy of KVD900 compared with placebo for the on-demand treatment of HAE attacks.Secondary Objective: To investigate the safety and tolerability of KVD900.
Approved WMOCompleted
Primary Objective:• To investigate the efficacy of KVD900 compared to placebo in halting the progression of a peripheral or abdominal attack of hereditary angioedema (HAE).Secondary Objectives:• To investigate the safety and tolerability of KVD900…